Clinical Trial Update: iGlarLixi CGM Study in Chinese T2D Individuals After OADs [Phase 4]

View source ↗

Summary

Sanofi is conducting a Phase 4 trial of the iGlarLixi fixed-ratio insulin glargine/lixisenatide in Chinese adults with type 2 diabetes after prior oral antidiab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• iGlarLixi (insulin glargine + lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes (T2D) | Phase 4 | Status: RECRUITING